BioLineRx begins phase 1/2a trial of GLIX1 for glioblastoma treatment

March 26, 2026 7:00 AM

BioLineRx Ltd. (NASDAQ: BLRX) has initiated a first-in-human Phase 1/2a clinical trial of GLIX1 for treating recurrent and progressive glioblastoma ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found